

Juha Mykkänen, PhD, Adjunct professor (title of docent)
SELECTED LIST OF PUBLICATIONS, 25.5.2018

A1. Journal article – refereed

1. Lietzen N, An Le TT, Jaakkola MK, Kallionpää H, Oikarinen S, **Mykkänen J**, Knip M, Veijola R, Ilonen J, Toppari J, Hyöty H, Lahesmaa R, Elo LL. Enterovirus-Associated Changes in Blood Transcriptomic Profiles of Children with Genetic Susceptibility to Type 1 Diabetes. *Diabetologia* 2018; 61:381-388.
2. Kurko J, Tringham M, Tanner L, Vähä-Mäkilä M, Lietzen N, Pöhö P, Mattila I, Olkku A, Hyötyläinen T, Orešič M, Simell O, Niinikoski H, **Mykkänen J**. Imbalance of plasma amino acids, metabolites and lipids in patients with lysinuric protein intolerance (LPI). *Metabolism* 2016; 65:1361–1375.
3. Törn C, Liu X, Hagopian W, Lernmark Å, Simell O, Rewers M, Ziegler AG, Schatz D, Akolkar B, Onengut-Gumuscu S, Chen WM, Toppari J, **Mykkänen J**, Ilonen J, Rich SS, She JX, Sharma A, Steck A, Krischer J; TEDDY Study Group. Complement gene variants in relation to autoantibodies to beta cell specific antigens and type 1 diabetes in the TEDDY Study. *Sci Rep* 2016; 6:27887.
4. Koskinen MK, Helminen O, Matomäki J, Aspholm S, **Mykkänen J**, Mäkinen M, Simell V, Vähä-Mäkilä M, Simell T, Ilonen J, Knip M, Veijola R, Toppari J, Simell OG. Reduced β -cell function in early preclinical type 1 diabetes. *Eur J Endocrinol* 2016; 174:251-9.
5. Mäkinen M, **Mykkänen J**, Koskinen M, Simell V, Veijola R, Hyöty H, Ilonen J, Knip M, Simell O, Toppari J. Serum 25-Hydroxyvitamin D Concentrations in Children Progressing to Autoimmunity and Clinical Type 1 Diabetes. *J Clin Endocrinol Metab* 2015; 101:723-9.
6. Kurko J, Tringham M, Tanner L, Vähä-Mäkilä M, Paavanen-Huhtala S, Saarinen M, Nantö-Salonen K, Simell O, Niinikoski H, **Mykkänen J**. Dysfunction of macrophage toll-like receptor signaling caused by an inborn error of cationic amino acid transport. *Mol Immunol* 2015; 67:416-25.
7. Moulder R, Bhosale S, Erkkilä T, Laajala E, Salmi J, Nguyen M, Kallionpää H, **Mykkänen J**, Vähä-Mäkilä M, Hyöty H, Veijola R, Ilonen J, Simell T, Toppari J, Knip M, Goodlett D, Lähdesmäki H, Simell O, Lahesmaa R. Serum Proteomes Distinguish Type-1 Diabetes Developing Children in a Cohort with HLA-conferred Susceptibility. *Diabetes* 2015; 64:2265-78.
8. Törn C, Hadley D, Lee HS, Hagopian W, Lernmark Å, Simell O, Rewers M, Ziegler A, Schatz D, Akolkar B, Onengut-Gumuscu S, Chen WM, Toppari J, **Mykkänen J**, Ilonen J, Rich SS, She JX, Steck AK, Krischer J and the TEDDY Study Group. Role of Type 1 diabetes associated SNPs on risk of autoantibody positivity in the TEDDY Study. *Diabetes* 2014; 64:1818-29.
9. Davis-Richardson AG, Ardisson AN, Dias R, Simell V, Leonard MT, Kempainen KM, Drew JC, Schatz D, Atkinson MA, Kolaczowski B, Ilonen J, Knip M, Toppari J, Nurminen N, Hyöty H, Veijola R, Simell T, **Mykkänen J**, Simell O and Triplett EW. *Bacteroides dorei* dominates gut microbiome prior to autoimmunity in Finnish children at high risk for type 1 diabetes. *Front Microbiol* 2014; 5:678.
10. Mäkinen M, Simell V, **Mykkänen J**, Ilonen J, Veijola R, Hyöty H, Knip M, Simell O, Toppari J, Hermann R. An Increase in Serum 25-Hydroxyvitamin D Concentrations Preceded a Plateau in Type 1 Diabetes Incidence in Finnish Children. *J Clin Endocrinol Metab* 2014; 99:E2353-6.
11. Kallionpää H*, Elo LL*, Laajala E*, **Mykkänen J**, Ricaño-Ponce I, Vaarma M, Laajala TD, Hyöty H, Ilonen J, Veijola R, Simell T, Wijmenga C, Knip M, Lähdesmäki H, Simell O, Lahesmaa R. Innate immune activity is detected prior to seroconversion in children with HLA-conferred type 1 diabetes susceptibility. *Diabetes* 2014; 63:2402-14. *Shared first authorship.
12. Orešič M, Gopalacharyulu P, **Mykkänen J**, Lietzen N, Mäkinen M, Nygren H, Simell V, Hyöty H, Veijola R, Ilonen J, Sysi-Aho M, Knip M, Hyötyläinen T, Simell O. Cord Serum Lipidome in Prediction of Islet Autoimmunity and Type 1 Diabetes. *Diabetes* 2013; 62:3268-74.
13. Nikula T, **Mykkänen J**, Simell O, Lahesmaa R. Genome-wide comparison of two RNA stabilizing reagents for transcriptional profiling of peripheral blood. *Transl Res* 2012; 161:181-8.

14. Tringham M, Kurko J, Tanner L, Tuikkala J, Nevalainen OS, Niinikoski H, Simell O, Nääntö-Salonen K, Hietala M, **Mykkänen J**. Exploring the transcriptomic variation caused by the Finnish founder mutation of lysinuric protein intolerance (LPI). *Mol Genet Metab* 2012; 105:408-15.
15. Elo LL*, **Mykkänen J***, Nikula T, Järvenpää H, Simell S, Aittokallio T, Hyöty H, Ilonen J, Veijola R, Simell T, Knip M, Simell O, Lahesmaa R. Early suppression of immune response pathways characterizes children with prediabetes in genome-wide gene expression profiling. *J Autoimmun* 2010; 35:70-6. *Shared first authorship.
16. Puomila K, Simell O, Huoponen K, **Mykkänen J**. Two alternative promoters regulate the expression of lysinuric protein intolerance gene *SLC7A7*. *Mol Genet Metab* 2007; 90:298-306.
17. **Mykkänen J**, Toivonen M, Kleemola M, Savontaus ML, Simell O, Aula P, Huoponen K. Promoter analysis of the human *SLC7A7* gene encoding y⁺L amino acid transporter-1 (y⁺LAT-1). *Biochem Biophys Res Commun* 2003; 301:855-61.
18. **Mykkänen J***, Torrents D*, Pineda M, Camps M, Yoldi ME, Horelli-Kuitunen N, Huoponen K, Heinonen M, Oksanen J, Simell O, Savontaus ML, Zorzano A, Palacín M, Aula P. Functional analysis of novel mutations in y⁺LAT-1 amino acid transporter gene causing lysinuric protein intolerance (LPI). *Hum Mol Genet* 2000; 9:431-38. *Shared first authorship.
19. Torrents D*, **Mykkänen J***, Pineda M, Feliubadalo L, Estevez R, de Cid R, Sanjurjo P, Zorzano A, Nunes V, Huoponen K, Reinikainen A, Simell O, Savontaus ML, Aula P, Palacin M. Identification of *SLC7A7*, encoding y⁺LAT-1, as the lysinuric protein intolerance gene. *Nat Genet* 1999; 21:293-96. *Shared first authorship.
20. Lauteala T, Sistonen P, Savontaus ML, **Mykkänen J**, Simell J, Lukkarinen M, Simell O, Aula P. Lysinuric protein intolerance (LPI) gene maps to the long arm of chromosome 14. *Am J Hum Genet* 1997; 60:1479-486.